Evidence map›Paper›PMID 27914702›Full record

ReviewKidney international2017

Renal xenotransplantation: experimental progress and clinical prospects.

Martin Wijkstrom, Hayato Iwase, Wayne Paris, Hidetaka Hara, Mohamed Ezzelarab, David K C Cooper

Open access · greenAbstract readHistorical ArticleReview
In one paragraph

Review in Kidney international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Immune Landscape in Kidney Transplantation.Journal of inflammation research · 2025
    Review
  5. Article
  6. Porcine Kidney Organoids Derived from Naïve-like Embryonic Stem Cells.International journal of molecular sciences · 2024
    Article
  7. From waste to wealth: Repurposing slaughterhouse waste for xenotransplantation.Frontiers in bioengineering and biotechnology · 2023
    Article
  8. Review
  9. Article
  10. Article
  11. Xenotransplantation: A New Era.Frontiers in immunology · 2022
    Review
  12. Review
  13. Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Long-term survival of pig-to-rhesus macaque renal xenografts is dependent on CD4 T cell depletion.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Martin WijkstromThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Hayato IwaseThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Wayne ParisSchool of Social Work, Abilene Christian University, Abilene, Texas, USA.
Hidetaka HaraThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Mohamed EzzelarabThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
David K C CooperThomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: cooperdk@upmc.edu.
University of Pittsburgh · USAbilene Christian University · US

Funding

Prolonging life-supported pig kidney and heart graft survival in baboons by suppressing inflammationU19AI090959 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2010 to 2024
$26.3M
Thromboregulation to Prevent Thrombotic MicroangiopathyU01AI068642 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2005 to 2008
$2.7M
Tolerance to Carbohydrate Antigens in TransplantationR21AI074844 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COOPER, DAVID KC · 2007 to 2008
$405k
NIAID NIH HHS R21 AI074844NIAID NIH HHS U01 AI068642NIAID NIH HHS U19 AI090959
6 · The paper itself

Abstract

There are >100,000 patients waiting for kidney transplants in the United States and a vast need worldwide. Xenotransplantation, in the form of the transplantation of kidneys from genetically engineered pigs, offers the possibility of overcoming the chronic shortage of deceased and living human donors. These genetic manipulations can take the form of (i) knockout of pig genes that are responsible for the expression of antigens against which the primate (human or nonhuman primate) has natural "preformed" antibodies that bind and initiate complement-mediated destruction or (ii) the insertion of human transgenes that provide protection against the human complement, coagulation, or inflammatory responses. Between 1989 and 2015, pig kidney graft survival in nonhuman primates increased from 23 days to almost 10 months. There appear to be no clinically significant physiological incompatibilities in renal function between pigs and primates. The organ-source pigs will be housed in a biosecure environment, and thus the risk of transferring an exogenous potentially pathogenic microorganism will be less than that after allotransplantation. Although the risk associated with porcine endogenous retroviruses is considered small, techniques are now available whereby they could potentially be excluded from the pig. The US Food and Drug Administration suggests that xenotransplantation should be restricted to "patients with serious or life-threatening diseases for whom adequately safe and effective alternative therapies are not available." These might include those with (i) a high degree of allosensitization to human leukocyte antigens or (ii) rapid recurrence of primary disease in previous allografts. The potential psychosocial, regulatory, and legal aspects of clinical xenotransplantation are briefly discussed.

Indexed as

Transplantation, HeterologousAnimalsAnimals, Genetically ModifiedGenotypeGraft RejectionGraft SurvivalHeterograftsHistory, 20th CenturyHistory, 21st CenturyHumansImmunosuppressive AgentsKidney TransplantationPhenotypeRisk FactorsSpecies SpecificitySus scrofaImmunosuppressive Agentsallosensitizationclinical trialgenetically engineered xenotransplantationkidneypig

Identifiers

PMID27914702
PMCPMC5357451
OpenAlexW2557775641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.